Search
Bortezomib Improves Survival in Children with Newly Diagnosed T-Cell Lymphoblastic Lymphoma
- OPACC
- Mar 28, 2022
- 1 min read
Adding the proteasome inhibitor bortezomib to chemotherapy significantly improved overall survival in children and young adults with newly diagnosed T-cell lymphoblastic lymphoma (T-LL).
Recent Posts
See AllQuality of life improvements can be made if clinicians better understand auditory attention decay after cancer treatment in pediatric...
A team of experts, issuing a statement on behalf of the American Heart Association, have detailed cardiometabolic considerations for...
While the overall prevalence of comorbidities at diagnosis in pediatric patients with acute lymphoblastic leukemia (ALL) and...
Comments